Remove 2011 Remove Patients Remove Pharmaceutical manufacturing Remove Prescription
article thumbnail

A Powerful Point-of-Sale Partnership that Delivers on the Promise of Affordable Insulin

PM360

This collaboration builds on Sanofi’s recent announcement to lower the list price for Lantus and cap OOP costs at $35 for all patients with commercial insurance, which goes into effect January 1, 2024. The price is available to cash-paying patients with a valid prescription. Currently, an estimated 37.3 of the U.S.

Retail 52
article thumbnail

Everything You Need to Know About Market Access in China

PM360

Medicines that are not listed in either Category 1 or 2, such as over the counter (OTC) and other prescription therapies (pembrolizumab, CAR-T therapy, etc.), The GBA gives patients access to innovative drugs (e.g., This also includes some innovative drugs in rare diseases and oncology with relatively high prices.

Marketing 105